Improving mesenchymal stem/stromal cell potency and survival: Proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congrès de Montréal, Organized by the ISCT MSC Scientific Committee

Jan A Nolta; Jacques Galipeau; Donald G Phinney

doi:10.1016/j.jcyt.2020.01.004

Improving mesenchymal stem/stromal cell potency and survival: Proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congrès de Montréal, Organized by the ISCT MSC Scientific Committee

Cytotherapy. 2020 Mar;22(3):123-126. doi: 10.1016/j.jcyt.2020.01.004. Epub 2020 Feb 15.

Authors

Jan A Nolta¹, Jacques Galipeau², Donald G Phinney³

Affiliations

¹ University of California Davis Stem Cell Program, Sacramento, California, USA. Electronic address: Janolta@ucdavis.edu.
² University of Wisconsin, Madison, Wisconsin, USA.
³ Scripps Research Institute, Jupiter, Florida, USA.

PMID: 32067856
DOI: 10.1016/j.jcyt.2020.01.004

Abstract

As part of the International Society of Cell Therapy (ISCT) 2018 Annual Meeting, the Mesenchymal Stem/Stromal Cell (MSC) committee organized a pre-conference, which covered methods of improving MSC engraftment and potency in vivo and clinical efficacy using MSC potency assays. The speakers examined methods to improve clinical efficacy using MSC potency assays and methods to improve MSC engraftment/homing/potency in vivo. Discussion of patient "responders" versus "non-responders" in clinical trials and working toward ways to identify them were also included.

Keywords: clinical trials; mesenchymal; potency; stem cells; stromal cells.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Biological Assay
Cell Survival
Cell- and Tissue-Based Therapy*
Clinical Trials as Topic
Humans
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells / cytology*
Societies, Scientific*
Treatment Outcome